<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476084</url>
  </required_header>
  <id_info>
    <org_study_id>149600</org_study_id>
    <nct_id>NCT02476084</nct_id>
  </id_info>
  <brief_title>Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients</brief_title>
  <acronym>BMUS</acronym>
  <official_title>Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients: a Pilot Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the kinetics of change in quantitative measures of
      joint inflammation by state of the art power Doppler vascular imaging and to identify
      biomarkers in biological samples (synovial biopsies, DNA, RNA, PBMC, serum, plasma, urine and
      stool samples) from parallel cohorts of RA patients undergoing different treatments. This
      will be achieved implementing MSUS assessments, standard laboratories techniques (such as
      ELISAs, gene profiling, transcriptome analysis etc.) and the novel CyTOF™ technology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in synovial thickness and vascularity using a limited joint set musculoskeletal ultrasound examination in Rheumatoid Arthritis.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the distribution of cell populations in biological samples from Rheumatoid Arthritis patients using CyTOF.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression in biological samples from Rheumatoid Arthritis patients using gene profiling.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokines' concentration in biological samples from Rheumatoid Arthritis patients using ELISA and transcriptome analysis.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <description>Naive RA patients commencing Methotrexate and Hydroxychloroquine.
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
    <description>Conventional synthetic DMARD inadequate responders commencing Anti-TNF
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <description>Conventional synthetic DMARD inadequate responders commencing anti-IL6
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <description>Conventional synthetic DMARD inadequate responders commencing anti-CTLA-4
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
    <description>Conventional synthetic DMARD inadequate responders commencing anti-CD20
Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Musculoskeletal Ultrasound Imaging</intervention_name>
    <description>B-mode and PD musculoskeletal ultrasound examination of selected joints.</description>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Synovial biopsy</intervention_name>
    <description>US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.</description>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological samples collection</intervention_name>
    <description>Draw of research blood samples.</description>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Administration of validated patients' questionnaires.</description>
    <arm_group_label>Conventional synthetic DMARD naïve</arm_group_label>
    <arm_group_label>DMARD-IR: anti-TNF</arm_group_label>
    <arm_group_label>DMARD-IR: anti-IL6</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CTLA-4</arm_group_label>
    <arm_group_label>DMARD-IR: anti-CD20</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and and Biologic samples collected will be processed in the CTU Translational Research
      Lab and stored within the Botnar Research Centre adhering to local guidelines on sample
      requirements, handling and storage. All biological samples will be available for future
      studies for biomarker profiling.

      The following blood samples will be drawn in order:

        1. Two (10.0ml) K2EDTA tube

        2. One (5.0ml) SST tube

        3. One (3 ml) Tempus RNA tube

        4. One (6 ml) DNA EDTA tube (only during Visit 1)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid Arthritis Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written confirmed diagnosis of Rheumatoid Arthritis as per ACR/EULAR 2010 criteria.

          -  If patient is on oral corticosteroids, dose must be stable for 6 weeks prior to
             baseline visit.

          -  Willingness and ability to comply with all the study procedures.

        Exclusion Criteria:

          -  Any systemic inflammation conditions (other than RA), connective tissue disease or
             chronic pain disorders that may interfere with the interpretation of the outcome data.
             Examples include psoriatic arthritis, reactive arthritis, gout, systemic lupus
             erythematosus (SLE), polymyalgia rheumatic and/or temporal arteritis, Lyme's disease,
             fibromyalgia and chronic fatigue syndromes.

          -  Major surgery planned within 8 weeks prior to screening or planned surgery throughout
             the study period.

          -  Treatment with any investigational agent ≤ 4 weeks prior to baseline (or 5 ≤
             half-lives of the investigational drug, whichever is the longer).

          -  Intramuscular/intra-articular glucocorticoids for 6 weeks prior to baseline visit.

          -  Active infection.

          -  Septic arthritis within a native joint within the last 12 months.

          -  Sepsis of a prosthetic joint within 12 months or indefinitely if the joint remains in
             situ.

          -  Known HIV or hepatitis B/C infection.

          -  Latent TB infection unless they have completed adequate antibiotic prophylaxis.

          -  Malignancy (other than basal cell carcinoma) within the last 10 years.

          -  New York Heart Association (NYHA) grade 3 or 4 congestive cardiac failure.

          -  Demyelinating disease.

          -  Presence of a transplanted organ (with the exception of a corneal transplant &gt; 3
             months prior to screening).

          -  Known recent substance abuse (drug or alcohol).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter C Taylor, MA, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kennedy Institute of Rheumatology, University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne Mcdonald</last_name>
    <phone>01865 737960</phone>
    <email>joanne.madonald@ndorms.ox.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kuljeet Bhamra, MBcHB, MRCP, MSc</last_name>
    <phone>01865 737954</phone>
    <email>kuljeet.bhamra@ndorms.ox.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nuffield Orthopaedic Centre</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Macdonald</last_name>
      <phone>+441865 737211</phone>
      <email>joanne.macdonald@ndorms.ox.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Peter Taylor</last_name>
      <phone>+441865 227323</phone>
      <email>peter.taylor@kennedy.ox.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Peter C Taylor, FRCP. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

